vs
Compass Therapeutics, Inc.（CMPX）与Dianthus Therapeutics, Inc.（DNTH）财务数据对比。点击上方公司名可切换其他公司
Compass Therapeutics, Inc.自由现金流更多（$-10.9M vs $-47.1M）
Compass Therapeutics是一家英国制药企业，主打研发迷幻类药物作为创新医疗方案，核心候选药物裸盖菇素（COMP360）目前已进入针对难治性抑郁症的三期临床试验，该药物还获得了美国FDA的突破性疗法认定，是当前进展领先的在研迷幻类候选药物之一。
Dianthus Therapeutics是一家临床阶段生物制药企业，专注开发罕见免疫与炎症疾病的新型靶向疗法，其抗体类候选管线聚焦解决重症患者未满足医疗需求，主要在北美开展临床研究与合作。
CMPX vs DNTH — 直观对比
营收规模更大
DNTH
是对方的Infinity倍
$0
自由现金流更多
CMPX
多$36.3M
$-47.1M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $284.0K |
| 净利润 | $-14.3M | $-64.4M |
| 毛利率 | — | — |
| 营业利润率 | — | -24486.3% |
| 净利率 | — | -22687.3% |
| 营收同比 | — | -78.6% |
| 净利润同比 | -36.0% | -126.6% |
| 每股收益（稀释后） | — | $-1.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMPXDNTH
| Q4 25 | — | $284.0K | ||
| Q3 25 | $0 | $396.0K | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | $0 | $2.2M | ||
| Q2 24 | $850.0K | $1.9M | ||
| Q1 24 | — | $874.0K |
净利润CMPXDNTH
| Q4 25 | — | $-64.4M | ||
| Q3 25 | $-14.3M | $-36.8M | ||
| Q2 25 | $-19.9M | — | ||
| Q1 25 | — | $-29.5M | ||
| Q4 24 | — | $-28.4M | ||
| Q3 24 | $-10.5M | $-25.2M | ||
| Q2 24 | $-13.1M | $-17.6M | ||
| Q1 24 | — | $-13.7M |
营业利润率CMPXDNTH
| Q4 25 | — | -24486.3% | ||
| Q3 25 | — | -10173.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -2852.7% | ||
| Q4 24 | — | -2406.9% | ||
| Q3 24 | — | -1376.6% | ||
| Q2 24 | -1770.0% | -1191.8% | ||
| Q1 24 | — | -2041.6% |
净利率CMPXDNTH
| Q4 25 | — | -22687.3% | ||
| Q3 25 | — | -9284.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -2537.5% | ||
| Q4 24 | — | -2144.8% | ||
| Q3 24 | — | -1159.0% | ||
| Q2 24 | -1538.4% | -945.1% | ||
| Q1 24 | — | -1573.0% |
每股收益（稀释后）CMPXDNTH
| Q4 25 | — | $-1.53 | ||
| Q3 25 | — | $-0.97 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.82 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.74 | ||
| Q2 24 | — | $-0.51 | ||
| Q1 24 | — | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $219.9M | $404.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $209.6M | $493.4M |
| 总资产 | $231.3M | $530.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CMPXDNTH
| Q4 25 | — | $404.3M | ||
| Q3 25 | $219.9M | $402.6M | ||
| Q2 25 | $100.9M | — | ||
| Q1 25 | — | $263.2M | ||
| Q4 24 | — | $275.2M | ||
| Q3 24 | $118.0M | $281.1M | ||
| Q2 24 | $146.2M | $360.7M | ||
| Q1 24 | — | $377.0M |
股东权益CMPXDNTH
| Q4 25 | — | $493.4M | ||
| Q3 25 | $209.6M | $546.5M | ||
| Q2 25 | $93.2M | — | ||
| Q1 25 | — | $328.6M | ||
| Q4 24 | — | $352.5M | ||
| Q3 24 | $138.4M | $337.9M | ||
| Q2 24 | $146.1M | $358.2M | ||
| Q1 24 | — | $372.7M |
总资产CMPXDNTH
| Q4 25 | — | $530.9M | ||
| Q3 25 | $231.3M | $577.4M | ||
| Q2 25 | $116.7M | — | ||
| Q1 25 | — | $348.6M | ||
| Q4 24 | — | $374.0M | ||
| Q3 24 | $149.2M | $354.2M | ||
| Q2 24 | $155.6M | $369.0M | ||
| Q1 24 | — | $382.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-10.8M | $-47.0M |
| 自由现金流经营现金流 - 资本支出 | $-10.9M | $-47.1M |
| 自由现金流率自由现金流/营收 | — | -16591.9% |
| 资本支出强度资本支出/营收 | — | 48.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-132.8M |
8季度趋势，按日历期对齐
经营现金流CMPXDNTH
| Q4 25 | — | $-47.0M | ||
| Q3 25 | $-10.8M | $-30.6M | ||
| Q2 25 | $-11.8M | — | ||
| Q1 25 | — | $-27.6M | ||
| Q4 24 | — | $-27.4M | ||
| Q3 24 | $-11.1M | $-21.3M | ||
| Q2 24 | $-10.8M | $-14.5M | ||
| Q1 24 | — | $-14.9M |
自由现金流CMPXDNTH
| Q4 25 | — | $-47.1M | ||
| Q3 25 | $-10.9M | $-30.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-27.7M | ||
| Q4 24 | — | $-27.5M | ||
| Q3 24 | $-11.1M | $-21.3M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-15.0M |
自由现金流率CMPXDNTH
| Q4 25 | — | -16591.9% | ||
| Q3 25 | — | -7717.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -2377.8% | ||
| Q4 24 | — | -2072.0% | ||
| Q3 24 | — | -980.3% | ||
| Q2 24 | — | -780.7% | ||
| Q1 24 | — | -1713.2% |
资本支出强度CMPXDNTH
| Q4 25 | — | 48.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | 0.0% | 0.9% | ||
| Q1 24 | — | 3.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
